# What Is KLOW Peptide? A Plain-English Overview | KLOW Peptide Research Dossier

> What is KLOW peptide? A plain-English overview of the four-peptide research blend — KPV, GHK-Cu, BPC-157, and TB-500 — what each component does, and what the combination has and hasn't been tested for.

The four-component blend explained without jargon — what each peptide is, what its research record covers, and where the combination's evidence runs out.

## In plain English

What is KLOW peptide? It is four separate research peptides dissolved together in one vial. The four are KPV, GHK-Cu, BPC-157, and TB-500. Each has its own published research record. None of them is FDA-approved. The combination has never been tested in a controlled study.

Here is the one-sentence version of each component's research role. KPV: a small anti-inflammatory peptide that quiets the molecular switch driving gut inflammation. GHK-Cu: a copper-bearing peptide that promotes collagen and affects a broad range of gene activity in skin cells. BPC-157: a synthetic peptide studied mostly in rats for tendon and tissue repair. TB-500: a small fragment of a larger protein linked to wound closure and cell movement, where most of the strong data come from the full-length protein, not this fragment.

KLOW is not a weight-loss compound. It is not a GLP-1 peptide. It is a research-only co-formulation used in laboratory settings, and the pages in this dossier document what the published research on each component has actually found.

## What is KLOW peptide made of?

KLOW is a co-formulation: multiple distinct compounds co-dissolved at fixed mass ratios in a single lyophilized vial. The most widely listed research composition is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. The peptides remain separate molecules after reconstitution; they do not react to form a new compound.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper(II) complex, CAS 89030-95-5, 402.92 Da) makes up about 62.5% of the canonical vial by mass. It is a naturally occurring tripeptide chelated to a copper ion, first isolated from human plasma in 1973. It is the reason reconstituted KLOW is blue-green: the copper(II) ion gives GHK-Cu that characteristic color, and at half the vial's mass it dominates the appearance of the solution.

KPV (Lys-Pro-Val, CAS 67727-97-3, 342.44 Da) is the anti-inflammatory arm — the C-terminal fragment of alpha-MSH, a 13-residue anti-inflammatory signaling peptide. It makes up 10 mg of the vial but represents, in the view of this dossier, the most mechanistically specific component: its documented NF-kappaB suppression and PepT1-mediated gut-epithelium uptake distinguish it from everything else in the stack [1].

BPC-157 (GEPPPGKPADDAGLV, CAS 137525-51-0, 1419.53 Da) is 10 mg of the vial — the largest molecule by molecular weight despite being a small share by mass. It is a 15-amino-acid synthetic peptide derived from a gastric-juice protein, studied in rodent tissue-repair models including transected Achilles tendon [2].

TB-500 (Ac-LKKTETQ, 889.02 Da) is the remaining 10 mg — a synthetic heptapeptide corresponding to the actin-binding motif of thymosin beta-4. Most of the wound-healing and cell-migration data cited for this arm come from the full-length 43-amino-acid native protein, not from this shorter fragment [3].

## What does KLOW do — and what is the combination gap?

Each component's research record supports a different mechanistic story. KPV suppresses NF-kappaB and MAPK signaling at nanomolar concentrations and is taken up into inflamed gut cells by the PepT1 transporter [1]. GHK-Cu stimulates collagen synthesis and modulates a broad transcriptomic program in fibroblasts toward matrix remodeling, antioxidant defense, and DNA repair [4, 5]. BPC-157 activates the VEGFR2 angiogenic pathway and has shown tissue-repair activity across a range of rodent injury models [2]. The TB-500 fragment sequesters G-actin, a step mechanistically linked to cell migration and wound closure.

The combination rationale — that these four arms address cytokine suppression, matrix remodeling, vascular supply, and cytoskeletal mobility as complementary steps of the same tissue-repair cascade — is a mechanistic hypothesis. It has not been tested in any controlled study of the four-peptide blend. No study has measured whether the combination produces additive, synergistic, or antagonistic effects relative to any component alone.

This is not a minor caveat. It is the central limitation of the KLOW literature — or, more precisely, of the KLOW non-literature. The published record for the blend is empty. Everything attributed to 'KLOW' in this dossier is attributed through the component it belongs to.

## How is KLOW different from other peptide blends?

KLOW's closest relative is the GLOW blend, which contains GHK-Cu, BPC-157, and TB-500. KLOW adds KPV as the fourth component. The KPV arm is the defining difference: NF-kappaB / MAPK suppression via PepT1-mediated gut-epithelium uptake is a pathway that none of the GLOW components targets [1]. Whether this addition changes clinical outcomes — in what populations, for what indications — is the question no controlled study has yet answered.

KLOW is also distinct from WOLVERINE, a research-community blend that combines BPC-157 and TB-500 in a two-component formulation. KLOW and WOLVERINE share two of their four and two components respectively, but KLOW adds the copper-peptide GHK-Cu arm and the anti-inflammatory KPV arm.

None of these blends — KLOW, GLOW, or WOLVERINE — has been tested in a controlled clinical trial. All are research-only co-formulations used in laboratory settings. The distinctions above are compositional; they do not imply outcome differences that any study has measured.

## KLOW research: status and compliance

KLOW is not FDA-approved. None of its four components is approved for human use as an individual compound. BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review. TB-500, as the synthetic fragment of thymosin beta-4, implicates the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition [7].

Human evidence for the component compounds individually is limited: GHK-Cu has substantial topical cosmetic and wound-healing data; BPC-157 has a 2025 IV safety pilot in two adults reporting no adverse events [6] and a small number of case series; thymosin beta-4 (not the TB-500 fragment) has early-phase trials; KPV human data are restricted to formulation pilots and its IBD-drug lineage. The combination blend has no human data at all.

For a detailed account of [what people report](/effects) — including the specific cautions for athletes, people with cancer, and people with copper-metabolism or autoimmune conditions — the effects page carries the full safety context.

---

A midnight-editorial dossier on four separate peptide literatures — each constituent kept to its own studies, the blend's column left blank because no controlled trial has filled it, and nothing here dispensed, dosed, or sold.